Walmart is expanding its health care benefits for employees, adding more than 250 prescription medications at no cost, including certain GLP-1 drugs, insulin products and inhalers.

The changes, announced Oct. 13, will expand prescription coverage under most of the retailer’s medical plans in 2027, according to Reuters and Fox Business.

The new benefit includes GLP-1 medications at no cost for eligible associates with Type 2 diabetes. Walmart said employees will need a new prior authorization approval to qualify for the free GLP-1 medications.

The changes arrive during Walmart’s annual benefits enrollment period, which runs through Nov. 6. The company employs about 1.6 million workers in the U.S, and about 37,400 in South Carolina, making it the country’s and the state’s largest private-sector employer. 

The retailer’s expanded prescription coverage includes more than 250 medications, including certain insulin products, inhalers and GLP-1 drugs. The company also highlighted medications for expensive conditions, including hemophilia and multiple sclerosis.

For example, Walmart said eligible employees taking Kesimpta, a medication for multiple sclerosis, will pay nothing for the drug in 2027 if they receive prior authorization approval. In 2026, those employees pay the greater of $50 or 20 percent of the drug’s allowable cost. The manufacturer list price is slightly more than $10,000 per month, according to Walmart.

Walmart is also expanding its Centers of Excellence benefit, which provides access to specialized medical care. Employees can now use the benefit to seek second opinions for serious conditions including multiple sclerosis, Parkinson’s disease and amyotrophic lateral sclerosis, or ALS. The program already provides access to care for serious conditions such as cancer through providers including Mayo Clinic and Cleveland Clinic.

Although the company is expanding coverage, employees will pay slightly more for its starting health insurance plan.